Kyte_jr

[Kyte_jr @Kyte_jr]

$RDGL

[DT_the_engineer @DT4873593182261]

Mayo needs to go through there IRB review process - good news is a Dr from Mayo Jacksonville site is on the Vivos Medical Advisory Board

[Kyte_jr @Kyte_jr]

$RDGL good question and answer

[Vivos Inc. @VivosIncUSA]

We’re pleased to share our new dedicated Investor Relations FAQ page, featuring answers to the most common questions we receive from our valued followers. Visit https://t.co/hANT0zshlu for the latest company information and updates. $RDGL

https://t.co/Avq83GrrHy

[Kyte_jr @Kyte_jr]

$RDGL peer reviewed publication, more progress

[Vivos Inc. @VivosIncUSA]

A press release was issued for the peer-reviewed publication for PrecisionGel™ in the Journal of Drug Delivery Science and Technology. PrecisionGel™ is the polymer carrier component of both @IsoPetForCancer and @RadioGel $RDGL

https://t.co/2DsNF39VZP

[Kyte_jr @Kyte_jr]

$RDGL this definitely a sleeper

[Upside Theory @DummyBoyFinance]

$rdgl This Cancer-Treatment Penny Stock Could EXPLODE | RDGL https://t.co/29OMIHXIpu via @YouTube

[Kyte_jr @Kyte_jr]

$RDGL more growth

[Vivos Inc. @VivosIncUSA]

A major milestone for Vivos! @IsoPetForCancer is officially shipping from our APEL facility in Richland, WA! In-house production strengthens supply, quality and scalability while positioning Vivos for continued growth in the U.S. and worldwide. $RDGL

[Kyte_jr @Kyte_jr]

$RDGL more progress

[Vivos Inc. @VivosIncUSA]

We are pleased to announce two significant operational milestones: the commencement of @IsoPetForCancer shipments from its new in-house U.S. production facility, and the receipt of authorization from AERB of India @RadioGel $RDGL

https://t.co/OHnzVq1m8P

[Kyte_jr @Kyte_jr]

@ClearUTL @TriCityHerald @RadioGel $RDGL great story of how effective @RadioGel is

[Alpha167🇺🇸 @ClearUTL]

🚨 70% tumor reduction in 30 days
✅ Undetectable at 60 days
🗣️ Voice saved

This is the result highlighted in the new @TriCityHerald coverage on @RadioGel as it heads into Mayo Clinic trials under the FDA IDE. $RDGL

[Kyte_jr @Kyte_jr]

https://t.co/pDovlMHw8t
$RDGL great story about @RadioGel and how it helped a teacher with cancer

[Kyte_jr @Kyte_jr]

$RDGL

[Vivos Inc. @VivosIncUSA]

Vivos Inc is pleased to announce the launch of our new corporate website that better reflects the Company’s vision, technology and continued growth in the field of innovative cancer treatment.
@RadioGel @IsoPetForCancer $RDGL

[Kyte_jr @Kyte_jr]

$RDGL

[RDGL INVESTORS GROUP @RDGLinvestors]

🚨 $RDGL Insider Confidence 🚨

CEO Michael Korenko just purchased 200,000 shares of Vivos Inc. , adding to his already significant ownership.

Last week, President Brad Weeks also stepped up and bought 60,000 shares.

When the people closest to the company are putting their own money behind RDGL, it sends a strong message: management believes in the opportunity ahead.

FDA IDE ✅
Mayo Clinic pathway ✅
Clinical milestone ahead

Insiders are positioning for what they believe comes next. $RDGL

SEC filing: https://t.co/vZNQNbv9oD

$RDGL #RadioGel #CancerResearch #MedTech #Biotech #SmallCapStocks

[Kyte_jr @Kyte_jr]

$RDGL insiders are buying

[Ragnar @1amgme]

$RDGL Vivos Inc (RDGL) CEO buys 200,000 common shares in open market
https://t.co/guaplkShMw

[Kyte_jr @Kyte_jr]

$RDGL Mayo trials will prove what we already know that @RadioGel is safe

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL Mayo Clinic Trial Timeline (Estimated) 🚀

With FDA IDE approval secured, the next major milestones could come quickly 👇

✅ IRB Approval: July–August 2026
Protocol updated per FDA feedback and moving through Mayo review.

✅ First Patient Dosed (FPD): August–September 2026
Small 5-patient feasibility study = faster enrollment.

✅ Early Safety Updates: September–October 2026
First human data could begin coming shortly after dosing.

✅ Full 5-Patient Readout: Q4 2026
Small study size allows for a potentially rapid completion.

Why this matters:
🔹 FPD = major validation milestone
🔹 Human data = first proof of Radiogel in patients
🔹 5-patient feasibility study = critical step toward the next phase

Potential market-moving catalysts:
🚀 IRB approval removes the final hurdle before patients
🚀 First patient dosed confirms clinical execution
🚀 Positive safety data could change investor perception
🚀 Successful feasibility results could accelerate the path toward a pivotal trial

What comes after:

➡️ FDA discussions on the pivotal trial pathway

➡️ Pivotal trial design and preparation for a larger approval-enabling study

The next few months could be a major transition point for $RDGL as Radiogel moves from regulatory approval into human clinical data.

The market often revalues biotech companies when they move from regulatory uncertainty to human clinical data.

(Estimated timeline ,actual timing depends on Mayo IRB and trial activation) $RDGL @VivosInc #Biotech #MedTech #CancerResearch #ClinicalTrials #SmallCapStocks

[Kyte_jr @Kyte_jr]

$RDGL good to see his confidence

[Hondo @JimTom44]

$rdgl @VivosIncUSA President Brad Weeks buys 60,000 shares at .08. Great symbolism here along with great buy point. Shareholders should be very confident. Just wait until initial Mayo results come out.
https://t.co/shk3T7hFKK

[Kyte_jr @Kyte_jr]

$RDGL I'm a long time investor, great to see human trials

[Brad Weeks @BradWeeks0331]

Our medical partners see huge potential here for non-resectable metastatic papillary thyroid cancer in the neck where repeat surgery carries significant risks and good alternatives are limited. This targeted Y-90 hydrogel offers a major improvement over what's currently available: destroying tumors while protecting critical structures. America leads in precision cancer innovation. Proud to partner on breakthroughs that give patients better options! 🇺🇸 $RDGL

[Kyte_jr @Kyte_jr]

$RDGL

[Vivos Inc. @VivosIncUSA]

With the recent FDA approval to initiate clinical trials, @RadioGel is advancing the treatment of metastatic tumors while preserving voice, swallowing function, and critical neck anatomy—outcomes that could make a profound difference for patients. $RDGL

[Kyte_jr @Kyte_jr]

$RDGL

[RadioGel® @RadioGel]

With the recent FDA approval to initiate clinical trials, RadioGel® is advancing the treatment of metastatic tumors while preserving voice, swallowing function, and critical neck anatomy—outcomes that could make a profound difference for patients. $RDGL

[Kyte_jr @Kyte_jr]

$RDGL looking forward to Mayo trials

[Vivos Inc. @VivosIncUSA]

Dr. Fisher states that histopathology confirmed no radiation-associated adverse effects in normal organs or tissues, reinforcing the strong safety profile of @RadioGel We’re proud to be working with the Mayo Clinic as we advance human clinical trials. $RDGL

[Kyte_jr @Kyte_jr]

$RDGL can't wait for trials to start

[Vivos Inc. @VivosIncUSA]

Following our FDA approval to initiate U.S. human trials with the Mayo Clinic, these words from our President, Mr. Brad Weeks, are truly encouraging. Our focus is now on advancing @RadioGel alongside our clinical partners. $RDGL

[Kyte_jr @Kyte_jr]

$RDGL great to see they finally succeed

[Alpha167🇺🇸 @ClearUTL]

After years of dedication, Vivos Inc., a small American company, just received FDA IDE approval to start the first U.S. human feasibility study for RadioGel, a targeted injectable hydrogel therapy for cancer.

CEO Dr. Michael Korenko’s long-held dream is finally moving closer to helping patients who need better options. Real innovation from a small team with a big purpose. @elonmusk @rihanna @RealHughJackman @Cristiano @MrBeast @mcuban @JeffBezos